product name Icariin
Description: Icariin is a potent cGMP-specific PDE5 inhibitor with IC50 of 0.432 μM, which is 167-fold more selective for PDE5 than PDE4. Icariin Phosphodiesterase (PDE) is a crucial regulator of cAMP/PKA signaling. PDEs are encoded by 21 genes which can be sdivided into 11 families according to the substrate specificities and subcellular localization. PDEs are widely expressed in neurons.
References: Asian J Androl. 2003 Mar;5(1):15-8.
676.66
Formula
C33H40O15
CAS No.
489-32-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 50 mg/mL (73.9 mM)
Water: <1 mg/mL
Ethanol: <1 mg/L
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Icariin inhibited the activity of PDE5 and PDE4 in a dose- andconcentration-dependent manner. The IC50of icariin on PDE5 was 0.43 µM and the IC50 on PDE4 was 73.50 µM. Icariin showed a selective inhibitory effect on cGMP-specific PDE5 compared to cAMP-specific PDE4. Icariincould also enhance the osteogenic differentiation of rat primary bone marrow stromal cells. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In castrated rats, a 4-week oral administration of icariinat 1 mg/kg/day and 5 mg/kg/day improved the erectile function and increased nNOS and iNOS expression. Icariin also showed its effect on stimulating angiogenesis in human endothelial cells. |
| Animal model | Rats |
| Formulation & Dosage | |
| References | Asian J Androl. 2003 Mar;5(1):15-8; Biochem Biophys Res Commun. 2008 Nov 14;376(2):404-8. |
